This Alnylam promotional website is intended for UK Healthcare Professionals Only. Adverse Event Reporting information can be found at the bottom of the page. Prescribing Information links can be found with the content that they relate to.

Heart Failure Society of America (HFSA) 2025 Congress, USA

hfsa-congress-usa-mobile

Transthyretin Amyloidosis (ATTR)

Heart Failure Society of America (HFSA) 2025

Congress Details

26-29 September 2025 | USA

Minneapolis, MN, USA

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to vutrisiran▼. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Congress Materials

hfsa

Presentation Type

Poster

Location

Minneapolis, MN, USA

Title

Efficacy of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy by baseline health status and quality of life

Access Prescribing Information

Helios-B

Presentation Type

Presentation

Location

Minneapolis, MN, USA

Title

Outcomes of the HELIOS-B monotherapy population: A post-hoc analysis censoring data following tafamidis initiation

Helios-B-analysis

Presentation Type

Presentation

Location

Minneapolis, MN, USA

Title

Evidence of Fewer Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B

Access Prescribing Information

Transthyretin Amyloidosis (ATTR)

Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B

JACC: Advances

Author(s)

Ronald M. Witteles, Pablo Garcia-Pavia, Caroline Morbach, et al

August 2025

Access Now Vutrisiran Prescribing Information

Preparation Date

March 2026

Job Code

MB-UK-00167

eu-attr-italy-mobile

Transthyretin Amyloidosis (ATTR)

European ATTR Amyloidosis Meeting (EU-ATTR) 2025

25-26 September 2025 ITALY

Preparation Date

March 2026

Job Code

MB-UK-00113

European Society of Cardiology (ESC) 2025 Congress, Spain

Transthyretin Amyloidosis (ATTR)

European Society of Cardiology (ESC) 2025

29 August - 1 September 2025 SPAIN

Preparation Date

March 2026

Job Code

MB-UK-00118

Transthyretin Amyloidosis (ATTR)

Realising the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis

Molecular Therapy Nucleic Acids

Author(s)

Martha Grogan, Farooq H. Sheikh, Brett W. Sperry

June 2025

Access Now Patisiran Prescribing Information Vutrisiran Prescribing Information

Preparation Date

March 2026

Job Code

MB-UK-00168

Heart Failure Association (HFA) 2025 Congress, Serbia

Transthyretin Amyloidosis (ATTR)

Heart Failure Association (HFA) 2025

17-20 May 2025 Serbia

Preparation Date

March 2026

Job Code

MB-UK-00127

Peripheral Nerve Society (PNS) 2025 Congress, UK

Transthyretin Amyloidosis (ATTR)

Peripheral Nerve Society (PNS) 2025

17-20 May 2025 UK

Preparation Date

March 2026

Job Code

MB-UK-00130

Preparation Date

March 2026

Job Code

MB-UK-00106

Login and Sign up

Left Image

RNAiScience is for healthcare professionals. By creating an account, you will have access to:

- All RNAi on-demand educational content
- Personalisation experience with ability to bookmark content for future reference

First Name *

Last Name *

Enter your Institution Email *

Password *

Country *

GMC or GPhC or NMC Number

Select Speciality *

Select Profession *

* Required Fields

By signing up, you agree to our Terms of Service and Privacy Policy.